Genetic Characteristics of Patients with Young-Onset Myelodysplastic Neoplasms.
Hyun-Young KimKeon Hee YooChul Won JungHee-Jin KimSun-Hee KimPublished in: Journal of clinical medicine (2023)
Myelodysplastic neoplasm (MDS) is a heterogeneous group of myeloid neoplasms affected by germline and somatic genetic alterations. The incidence of MDS increases with age but rarely occurs at a young age. We investigated the germline and somatic genetic alterations of Korean patients with young-onset MDS (<40 years). Among the thirty-one patients, five (16.1%) had causative germline variants predisposing them to myeloid neoplasms (three with GATA2 variants and one each with PGM3 and ETV variants). We found that PGM3 deficiency, a subtype of severe immunodeficiency, predisposes patients to MDS. Somatic mutations were identified in 14 patients (45.2%), with lower rates in patients aged < 20 years (11.1%). Nine (29%) patients had U2AF1 S34F/Y mutations, and patients with U2AF1 mutations showed significantly worse progression-free survival ( p < 0.001) and overall survival ( p = 0.006) than those without U2AF1 mutations. A UBA1 M41T mutation that causes VEXAS syndrome was identified in a male patient. In conclusion, a germline predisposition to myeloid neoplasms occurred in ~16% of young-onset MDS patients and was largely associated with primary immunodeficiencies, including GATA2 deficiency. Furthermore, the high frequency of somatic U2AF1 mutations in patients with young-onset MDS suggests the presence of a distinct MDS subtype.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- copy number
- newly diagnosed
- peritoneal dialysis
- high frequency
- acute myeloid leukemia
- prognostic factors
- bone marrow
- atrial fibrillation
- free survival
- patient reported outcomes
- transcription factor
- dna repair
- case report
- single molecule
- risk factors
- low grade